Clinical Trials
28 trialsNCT05461430 2026-04-13
TraveraRTGx
Travera Inc
Completed
NCT05325866 2026-02-04
FORTITUDE-301
Amgen
Phase 1/2 Completed
NCT04853017 2025-09-05
AMPLIFY-201
Elicio Therapeutics
Phase 1 Completed
NCT05292859 2025-07-30
Long-Term Follow-up Study of Subjects Treated With Autologous T Cells Using the Sleeping Beauty System to Express TCRs
Alaunos Therapeutics
Completed
NCT05788484 2025-06-15
A Study of CDX-585 in Patients With Advanced Malignancies
Celldex Therapeutics
Phase 1 Completed
NCT05253053 2025-06-12
To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors
TransThera Sciences (Nanjing), Inc.
Phase 1/2 Completed
NCT02699606 2025-04-27
A Study to Evaluate the Clinical Efficacy of JNJ-42756493 (Erdafitinib), A Pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor, In Asian Participants With Advanced Non-Small-Cell Lung Cancer, Urothelial Cancer, Esophageal Cancer Or Cholangiocarcinoma
Janssen Research & Development, LLC
Phase 2 Completed
NCT03821233 2025-01-29
A Dose Finding Study of ZW49 in Patients With HER2-Positive Cancers
Zymeworks BC Inc.
Phase 1 Completed
NCT04028479 2024-12-18
ROOT
Taproot Health
Completed
NCT04672434 2024-12-09
Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies
Symphogen A/S
Phase 1 Completed
NCT04742959 2024-04-26
Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors
TransThera Sciences (Nanjing), Inc.
Phase 1/2 Completed
NCT03329950 2024-03-28
A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies
Celldex Therapeutics
Phase 1 Completed
NCT03665285 2024-03-08
A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors
NextCure, Inc.
Phase 1/2 Completed
NCT03219268 2023-12-21
A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms
MacroGenics
Phase 1 Completed
NCT03207347 2023-09-15
A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001)
University of Florida
Phase 2 Completed
NCT03602079 2023-08-03
Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene
Klus Pharma Inc.
Phase 1/2 Completed
NCT03829436 2023-07-03
TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers
Tempest Therapeutics
Phase 1 Completed
NCT04440943 2023-06-18
A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies
Celldex Therapeutics
Phase 1 Completed
NCT03849469 2023-03-30
DUET-4
Xencor, Inc.
Phase 1 Completed
NCT04430842 2023-01-18
Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S
Quadriga Biosciences, Inc.
Phase 1 Completed
NCT03517488 2022-12-01
DUET-2
Xencor, Inc.
Phase 1 Completed
NCT03102320 2022-06-30
ARCS-Multi
Bayer
Phase 1 Completed
NCT03071757 2022-04-28
A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors
AbbVie
Phase 1 Completed
NCT03000257 2022-04-14
A Study of Budigalimab (ABBV-181) in Participants With Advanced Solid Tumors
AbbVie
Phase 1 Completed
NCT03644173 2021-10-15
Personal Resilience Empowerment Program Study
Hackensack Meridian Health
Phase NA Completed
NCT01773655 2020-07-01
Clinical and Histopathologic Characteristics of BAP1 Mutations
Memorial Sloan Kettering Cancer Center
Completed
NCT00475956 2010-04-15
Safety and Tolerability Study of AZD2171 in Combination With AZD0530 in Patients With Advanced Solid Tumours
AstraZeneca
Phase 1 Completed
NCT00041808 2005-06-24
Magnetic-Targeted Doxorubicin in Treating Patients With Cancer Metastatic to the Liver
FeRx
Phase 1/2 Completed